FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 292:1366-1371 June 26, 1975 Number 26 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In an attempt to confirm three reports suggesting a causal link between rauwolfia antihypertensive drugs and female breast carcinoma, all cases of such cancer appearing among the residents of an affluent retirement community were compared with controls chosen from a roster of all women in the same community. Most residents use a single care facility, and patterns of hypertension diagnosis, rauwolfia and other drug use, and medical-care-system patronage were abstracted from medical records. The prevalence of recorded rauwolfia use among the controls were 20 per cent, and that of other drug use was correspondingly high. The risk ratio for rauwolfia use was estimated to be 1.2 (95 per cent confidence interval, 0.7 to 2.2). Risk ratios between 1.0 and 2.0 were also found for other drug use and for measures of care-system patronage. These results do not support the hypothesis that reserpine causes breast cancer.

This article has been cited by other articles:

• Alves Correa, S. A., Ribeiro de Noronha, S. M., Nogueira-de-Souza, N. C., Valleta de Carvalho, C., Massad Costa, A. M., Juvenal Linhares, J., Vieira Gomes, M. T., Guerreiro da Silva, I. D. C. (2009). Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. Journal of Renin-Angiotensin-Aldosterone System 10: 51-58 [Abstract]  
• Haiman, C. A., Henderson, S. O., Bretsky, P., Kolonel, L. N., Henderson, B. E. (2003). Genetic Variation in Angiotensin I-Converting Enzyme (ACE) and Breast Cancer Risk: The Multiethnic Cohort. Cancer Res. 63: 6984-6987 [Abstract] [Full Text]  
• Srikanth, V. K., Thrift, A. G., Saling, M. M., Anderson, J. F.I., Dewey, H. M., Macdonell, R. A.L., Donnan, G. A. (2003). Increased Risk of Cognitive Impairment 3 Months After Mild to Moderate First-Ever Stroke: A Community-Based Prospective Study of Nonaphasic English-Speaking Survivors. Stroke 34: 1136-1143 [Abstract] [Full Text]  
• Clevenger, C. V., Furth, P. A., Hankinson, S. E., Schuler, L. A. (2003). The Role of Prolactin in Mammary Carcinoma. Endocr. Rev. 24: 1-27 [Abstract] [Full Text]  
• Grossman, E, Messerli, F.H, Goldbourt, U (2001). Antihypertensive therapy and the risk of malignancies. Eur Heart J 22: 1343-1352 [Abstract]  
• Soler, M., Chatenoud, L., Negri, E., Parazzini, F., Franceschi, S., La Vecchia, C. (1999). Hypertension and Hormone-Related Neoplasms in Women. Hypertension 34: 320-325 [Abstract] [Full Text]  
• Hankinson, S. E., Willett, W. C., Michaud, D. S., Manson, J. E., Colditz, G. A., Longcope, C., Rosner, B., Speizer, F. E. (1999). Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women. JNCI J Natl Cancer Inst 91: 629-634 [Abstract] [Full Text]  
• Gambrell, R. D. Jr (1996). Hormone Replacement Therapy and Breast Cancer Risk. Arch Fam Med 5: 341-348 [Abstract]  
• Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., Ernster, V. L., Cummings, S. R. (1992). Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women. ANN INTERN MED 117: 1016-1037 [Abstract]  
• Steinberg, K. K., Thacker, S. B., Smith, S. J., Stroup, D. F., Zack, M. M., Flanders, W. D., Berkelman, R. L. (1991). A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer. JAMA 265: 1985-1990 [Abstract]  
• Dupont, W. D., Page, D. L. (1991). Menopausal Estrogen Replacement Therapy and Breast Cancer. Arch Intern Med 151: 67-72 [Abstract]  
• Horwitz, R. I., Feinstein, A. R. (1985). Exclusion Bias and the False Relationship of Reserpine and Breast Cancer. Arch Intern Med 145: 1873-1875 [Abstract]  
• Labarthe, D. R., O'Fallon, W. M. (1980). Reserpine and Breast Cancer: A Community-Based Longitudinal Study of 2,000 Hypertensive Women. JAMA 243: 2304-2310 [Abstract]  
• Schyve, P. M., Smithline, F., Meltzer, H. Y. (1978). Neuroleptic-induced Prolactin Level Elevation and Breast Cancer: An Emerging Clinical Issue. Arch Gen Psychiatry 35: 1291-1301 [Abstract]  
• Lee, P. A., Kelly, M. R., Wallin, J. D. (1976). Increased Prolactin Levels During Reserpine Treatment of Hypertensive Patients. JAMA 235: 2316-2317 [Abstract]  
• Jick, H. (1975). Reserpine and Breast Cancer: A Perspective. JAMA 233: 896-897 [Abstract]